title: Metastatic Renal Cell Carcinoma in a Renal Allograft: A Sustained Complete Remission After Stimulated Rejection.
abstract: We report the case of a 40-year-old woman who recovered from a diffuse metastatic renal cell carcinoma that developed from a kidney allograft. She was successfully treated by the induction of tumor rejection. Immunosuppression was discontinued, and transplant nephrectomy was deliberately delayed based on the expectation that the tumor mass would trigger the alloimmune response, which was stimulated with pegylated interferon-α-2a. Three years later, the patient remained in complete remission. Despite this severe context, the present case shows that the poor prognosis of allograft metastatic renal cell carcinoma could be dramatically reversed by taking advantage of the donor tumor origin to actively induce a specific alloimmune rejection of the tumor.
authors.affiliation: Department of Nephrology, AP-HP, DHU FIRE, Bichat Hospital, Paris, France.
authors.forename: L
authors.initials: L
authors.lastname: Champion
authors.affiliation: Department of Medical Oncology, APHP, Saint Louis Hospital, Paris, France.
authors.forename: S
authors.initials: S
authors.lastname: Culine
authors.affiliation: Department of Urology, APHP, Saint Louis Hospital, Paris, France.
authors.forename: F
authors.initials: F
authors.lastname: Desgranchamps
authors.affiliation: Department of Nuclear Medicine, AP-HP, Bichat Hospital, Paris, France.
authors.forename: K
authors.initials: K
authors.lastname: Benali
authors.affiliation: Department of Pathology, AP-HP, Saint Louis Hospital, Paris, France.
authors.forename: J
authors.initials: J
authors.lastname: Verine
authors.affiliation: Department of Nephrology, AP-HP, DHU FIRE, Bichat Hospital, Paris, France.
authors.forename: E
authors.initials: E
authors.lastname: Daugas
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000209:etiology / Q000556:secondary; D005260:Female; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D016030:Kidney Transplantation / Q000009:adverse effects*; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000627:therapeutic use; D012074:Remission Induction; D014184:Transplantation, Homologous
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C100416:peginterferon alfa-2a
keywords: cancer/malignancy/neoplasia: metastatic disease; clinical research/practice; kidney transplantation/nephrology; liver disease: malignant